Introduction: Results of recent clinical studies of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM) have dampened initial enthusiasm. However, the immune environment and targets of these treatments such as programmed cell death protein 1 and its ligand programmed death ligand 1 (PD-L1) have not been well characterized in MPM. Using a large cohort of patients, we investigated PD-L1 expression, immune infiltrates, and genome-wide copy number status and correlated them to clinicopathological features.
Introduction
Despite several trials investigating novel therapies in malignant pleural mesothelioma (MPM), there have been no practice-changing therapies since pemetrexed and cisplatin were found in a phase III trial to improve survival over cisplatin alone. 1, 2 Immune checkpoint inhibition therapy has shifted treatment paradigms in many types of cancers and some recent data have shown promise for improving MPM treatment. [3] [4] [5] [6] However, response to checkpoint inhibition therapy has been neither uniform nor predictable. To date, programmed death ligand 1 (PD-L1) expression in both tumor and immune cells has been the most readily assayable marker. Although there are many caveats to its expression and predictive power, it remains in wide use for its ability to enrich patients likely to respond and for its ease of application as an immunohistochemical (IHC) assay.
MPM was thought to be potentially immunogenic, as its pathogenesis involves substantial inflammation, but recent studies have tempered the initial enthusiasm for immune checkpoint inhibition. 7 The large phase IIb DETERMINE study demonstrated no overall survival (OS) benefit for the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody tremelimumab relative to placebo. 8 Recent data confirm that mutational load in MPM is low, 9 which may in part explain why the results of the DETERMINE study were negative: in both melanoma and NSCLC, mutational load is a predictor of benefit from CTLA-4 or programmed cell death protein 1 (PD-1) inhibition. 10, 11 Structural aberrations resulting in gene copy number gains and losses are thought to be common in the MPM genome, but whether their burden or pattern influences the immunogenicity and tumor immune microenvironment in MPM has not been studied.
PD-L1 is one of two ligands for PD-1. Inhibition of PD-1-PD-L1 interaction leads to continued T-cell activation, thus potentiating antitumor activity. 12 Data on PD-L1 expression in MPM are limited, and reported series have typically included small numbers of patients with positivity ranging from 20% to 50%. [13] [14] [15] Using a tissue microarray (TMA) containing a large cohort of 329 MPM samples, we sought to characterize the tumor-immune cell interface and correlate this with clinicopathological features and copy number profiles.
Materials and Methods
Under an ethics committee-approved protocol, clinical information on patient demographics, comorbidities, treatments, follow-up, and outcome was retrieved from medical records.
TMA and IHC Analysis
After histological confirmation of diagnosis (see the Supplementary Methods), TMAs were created by using a tissue arrayer (Tissue Arrayer I, Beecher Instruments Inc., Sun Prairie, WI) with 1-mm cores in triplicate from each patient's sample placed sequentially. Representative cores were chosen on the basis of tumor cellularity and the interface with tumor stroma. Four-micrometer sections of the TMAs were cut and stained with cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), forkhead box P3 (FOXP3), and PD-L1 antibodies as previously published. 16 In brief, we used the anti-CD4 rabbit immunoglobulin G (IgG) (Cell Marque, Rocklin, CA) at a concentration of 1.0 mg/mL, anti-CD8 mouse IgG1 clone C8/144B (Dako, Glostrup, Denmark), anti-FOXP3 mouse IgG1 (Abcam, Cambridge, MA) at a concentration of 17.0 mg/mL, and anti-PD-L1 rabbit IgG (E1L3N) (Cell Signaling Technology) at a concentration of 7.0 mg/mL. Antigen retrieval for PD-L1 and FOXP3 was carried out by boiling in a microwave for 15 minutes in target retrieval solution (pH 9) (Dako). For CD4 and CD8, we used cell conditioning (CC1) buffer (pH 8.5) (Ventana Medical Systems, Tucson, AZ) at 95 C for 52 minutes. A horseradish peroxidase system was used to detect signals. For all T-cell markers tonsil tissue was used as a positive control, and for PD-L1 placenta was the positive control.
Quantification for CD4-positive, CD8-positive, and FOXP3-positive lymphocytes was performed by using the Leica Aperio positive pixel count algorithm, version 9.1 (Leica Biosystems, Nussloch, Germany) as previously described 17 and expressed as the number of cells per 1000 tumor cells. A subset was validated by manual count. An average of the counts in all evaluable cores was taken for the statistical analysis. For PD-L1 staining, we considered at least 5% membranous staining (regardless of intensity) as positive 16, 18 and at least 50% moderate or intense staining as highly positive. 19 Samples with only cytoplasmic staining were considered negative and we did not score the PD-L1 expression on infiltrating cells. The IHC scoring was conducted independently by investigators B. T., M.A., K.A., and S. D. (authors K. A. and S. D. are experienced pathologists). For PD-L1 scoring (by B. T. and K. A.), the initial k score was 0.74 and discrepancies were settled by joint discussion. Cores with minimal or no tumor tissue and those with tumor necrosis were excluded from all analyses.
Statistics
OS was calculated from the time of initial diagnosis to death or last follow-up; patients who were lost to follow-up or were alive were censored. Descriptive statistics were used for clinicopathological data. Comparisons of different parameters between the groups with respect to PD-L1 expression were performed by using an analysis of variance test for continuous variables and Fisher's exact test for categorical variables. Values for neutrophil-to-lymphocyte ratio (NLR); CD4-positive, CD8-positive, and FOXP3-positive lymphocyte counts; and CD4-positive-to-CD8-positive, FOXP3-positive-to-CD4-positive, and FOXP3-positive-to-CD8-positive lymphocyte ratios were dichotomized using the median. For survival analysis, a Wald-type test from Cox's proportional hazard (PH) model was performed in the R statistical environment.
DNA Extraction and Copy Number Analysis
A representative subset of patient tumors (n ¼ 113) were selected for copy number analysis. One-millimeter cores were taken from tumor blocks corresponding to sections marked by the pathologist (K.A.). Copy number profiles were studied by using Affymetrix OncoScan Express SNP arrays (Affymetrix, Santa Clara, CA) and data were processed with Nexus Express (Biodiscovery, El Segundo, CA). After removing 13 low-quality samples (samples [EGA Study Accession: EGAS00001002323] that showed median absolute pairwise difference scores higher than 0.3 and displayed a high level of noise), we computed the percent genome aberration (PGA) for each sample. PGA was calculated as the total count of base pairs involved in copy number gains or losses divided by the total length of the genome in base pairs. 20 Mutated genes were defined on the basis of hg19 reference genome and the GENCODE reference gene annotation. 21 We first identified significantly recurrent copy number aberrations (CNAs) using GISTIC 2.0 22 with the default settings and also investigated the patterns in CNA occurrence among patients. Consensus clustering was used to group patients on the basis of ternarized CNA profiles (neutral, loss, or gain) for genes by using hierarchical clustering with Jaccard distance and 1000 repetitions. We considered up to six clusters and determined optimal cluster number by maximizing average item consensus and inspecting the consensus matrices.
Results
Between 1988 and 2014, 373 patients with MPM were captured within our database. After patients with inadequate formalin-fixed paraffin-embedded samples were excluded, TMAs were constructed from the tissues of 329 patients with confirmed MPM.
Demographic data are summarized in Supplementary  Table 1 . The median OS was 12.06 months. On univariate analysis, advanced age, history of significant weight loss, Eastern Cooperative Oncology Group performance status higher than 2, nonepithelioid histological subtype, higher stage (III and IV), and high NLR (>3.94) were found to be related to poorer outcomes (Supplementary Table 2 ).
Immunological Characterization
Among 311 evaluable samples, 130 (41.8%) were PD-L1-positive but only 30 (9.64%) were highly PD-L1-positive (Fig. 1 ). There was a strong correlation between PD-L1 expression and nonepithelioid histological subtype (Table 1) . When samples were dichotomized on the basis of levels of infiltration with CD4-positive, CD8-positive, and FOXP3-positive cells using the median, a higher level of infiltration was seen in patients who were highly PD-L1-positive (see Table 1 ). However, PD-L1-positive tumors also showed significantly increased CD4-positive and CD8-positive cell infiltration but not FOXP3-positive cell infiltration.
Relationship between PD-L1 Status and Immune Infiltration with Survival
Patients with PD-L1-positive tumors had a nonsignificant trend toward poorer OS (9.8 versus 13.5 months) (HR ¼ 1.19, 95% confidence interval [CI]: 0.91-1.53, Wald-type p ¼ 0.15). However, when the analysis was restricted to those who were strongly positive, high PD-L1-positive expression was associated with a significantly worse OS (HR ¼ 2.37, 95% CI: 1.57-3.56, Wald-type p <0.001). The poorer prognosis associated with high PD-L1-positive status was maintained even when the epithelioid and nonepithelioid subtypes were analyzed separately (Fig. 2) .
When dichotomized by the median, levels of CD4-positive, CD8-positive, and FOXP3-positive infiltration demonstrated no association with survival, although patients with high CD4-positive-to-CD8-positive ratios achieved better survival (HR ¼ 0.71, CI: 0.55-0.90, Waldtype p ¼ 0.005).
Histological subtype, stage, NLR, and CD4-positiveto-CD8-positive ratio were found to remain significant on multivariate analysis. However, high PD-L-positive status failed the Schoenfeld residual test to validate the PH assumptions, suggesting that that its effect changes with time. When Schoenfeld residuals were plotted, 10 months was found to represent a turning point and was therefore chosen as a threshold. When a multivariate Cox model with time-variate HRs was performed, we found that although these parameters had a significant effect in the earlier period (within 10 months), their effect faded thereafter (Table 2 ). When the cohort was stratified by histological subtype, we found that the effect of high PD-L1-positive status was time dependent in the nonepithelioid histological subtype but stayed constant with an HR greater than 6 in the epithelioid cohort (see Table 2 ).
Association of CNAs with PD-L1 Status, Tumor Histological Subtype, and Survival
Our data revealed a median of 147 CNAs (range 3-866) per sample with losses (median 79, range 3-516) being more common than gains (median 57, range 0-516).
PGA in individual samples ranged from 0.1% to 55.5% (median 15.2). Using consensus clustering to group patients on the basis of CNA profiles, we identified two primary clusters (Fig. 3) . Cluster 1 showed a significantly higher PGA than cluster 2 (Wilcoxon test p <0.001), but cluster membership was not found to be prognostic (HR ¼ 0.99, 95% CI: 0.65-1.51, Cox PH p ¼ 0.97) and did not correlate with PD-L1 status (Fisher's exact test p ¼ 0.76). Interestingly, cluster 2 contained a greater proportion of nonepithelioid MPMs (Fisher exact test p ¼ 0.03). PGA was significantly higher in epithelioid than nonepithelioid tumors (Supplementary Fig. 1 ) but did not correlate with patient sex, asbestos exposure status, stage, and (importantly) PD-L1 status. Patients with a lower PGA had significantly higher infiltration with CD4-positive (t test p ¼ 0.03) and CD8-positive (t test p ¼ 0.001) cells. When patients were dichomatized by the tertiles (lower third versus upper two-thirds), patients with a lower PGA achieved better survival (HR ¼ 2.01, 95% CI: 1.24-3.26, Cox PH p ¼ 0.004) after controlling for age and tumor stage. This was true when the epithelioid and nonepithelioid tumors were analyzed separately (Fig. 4) .
We initially divided the groups into test and validation cohorts with the same result. When counts of individual CNAs among the PD-L1 groups were compared by using Fisher's exact test at each gene, none was found to be significantly associated with PD-L1 status after correction for multiple testing.
Discussion
Using a clinically well-annotated TMA, we have demonstrated that PD-L1 is strongly expressed in a subset of mesotheliomas, but most were weakly positive or negative. The strongly positive samples were associated with immune infiltration of CD4-positive, CD8-positive, and FOXP3-positive lymphocytes, as well as with poorer survival, in a time-dependent fashion. Although we found a large number of CNAs, neither the PGA nor any particular CNA was found to be associated with PD-L1 expression. Intriguingly, PGA was higher among epithelioid MPMs, and yet higher PGA was associated with poorer survival.
Using a predefined stringent scoring criteria in accordance with previous reports, 18, 19 we observed a 14 reported a 40% positivity rate in 106 patients when they regarded both cytoplasmic and membranous staining with 5% taken as a cutoff. They found a lower rate (24%) of exclusive membranous staining. Cedrés et al. 13 found 20% positivity in their 77 evaluable patients despite considering cytoplasmic and membranous staining and staining of infiltrating lymphocytes. Lack of uniformity in staining procedures, use of different antibodies, differing cutoffs, and also the fact that PD-L1 expression is dynamic and heterogeneous within the tumor makes comparison between different series difficult. 23 Given that nonepithelioid MPMs are more likely to be PD-L1-positive, the comparatively lower positivity rates noted by Cedrés et al. 13 may be explained by a larger proportion of epithelioid MPM in their series. Mansfield et al.
14 used a different antibody (clone 5H1-A3). The effect of different antibodies on PD-L1 positivity rates was recently demonstrated by Combaz-Lair et al. 15 In their 58 patients with MPM, when 1% membranous staining was used as the cutoff, they found 50% (29 of 58) positivity with clone E1L3N (Cell Signaling Technology) and 29% (17 of 58) with clone SP142 from Spring Bioscience (Pleasanton, CA). However, these numbers were limited and full face was used for IHC. 15 Setting a higher benchmark by defining a group with very high expression (50% staining in our case) may therefore help identify the truly positive cases. Also, the location of PD-L1 on tumor cells is thought to be germane to its prognostic role. It is presumed that membranous expression is the most relevant form of PD-L1 because PD-1 mediates downstream signalling cascades only when it has been ligated. 24 Cytosolic PD-L1 has not been reported to correlate with patient response to immunotherapy, and as such its importance is unclear. 25, 26 A significant finding of our study was the correlation of PD-L1 expression with tumor-infiltrating lymphocytes. Increased CD8-positive T-cell counts with high PD-L1positivity is in keeping with the current understanding that the PD-1-PD-L1 interaction results in clonal proliferation of CD8-positive lymphocytes that are functionally impaired. 27 A similar correlation was observed by Cedrés et al., 13 such that tumors with increased CD8-positive and CD4-positive tumorinfiltrating lymphocyte counts were seen in 68% and 59% of PD-L1-positive patients, respectively. The antibody used for our IHC (E1L3N XP) has been known to stain immune cells and could potentially confound these results; however, we have tried to avoid this by scoring PD-L1 expression exclusively on malignant cells and discounting the immune infiltrates. This study confirmed the findings of the two smaller studies 13, 14 showing that PD-L1 positivity was related to worse outcome. However, the association with survival was lost in multivariate analysis when histological subtype was included in the model, suggesting that the poor outcome seen in PD-L1-positive patients was more a function of histological subtype rather than PD-L1 expression alone. Analyses of survival restricted to 
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Mesothelioma: Immunological Characterizationhigh PD-L1 positivity showed the hazard associated to be significant but time dependent. Time variance of risks is thought to be common in oncology-related studies with long follow-up, although it is only looked for and reported in a very small proportion of studies. 28 Our finding of a constant HR higher than 6 among epithelioid MPMs could suggest that patients with high PD-L1-positive status would stand to benefit more from ant-PD-1/PD-L1 therapy. However, the proportion of these patients in our cohort of epithelioid patients (seven of 154 [4%]) was small and therefore this finding needs to be validated in another cohort.
The association between PD-L1 positivity and histological subtype is an important finding because it has been consistent in all reported series. Given that PD-L1 expression on tumor cells has to date been the most promising predictive biomarker, 29, 30 our data suggest that nonepithelioid mesothelioma, which is a disease with few treatment options and universally poor outcomes, may be best suited to these therapies. Interestingly, given their overall poorer prognosis, such patients are rarely eligible for clinical trials and so there are limited data currently available for these subtypes.
The concept that effective checkpoint inhibition therapy requires T-cell responses to neoantigens secondary to mutational burden in cancer cells has been substantiated in recent studies in melanoma 11 and lung cancer. 10 The mutational load of MPM is known to be relatively low, 9 and yet, there have been some reports of encouraging response to checkpoint inhibition therapy in MPM. CNAs have been reported as the predominant genetic aberrations in MPM 31 and are thought to be able to produce proteins with new and modified activities. 32 This study did not find a significant association between the PGA and frequency of individual CNA with PD-L1 status. We did however find that lower PGA was associated with better survival, and intriguingly, despite having higher rates of PD-L1 positivity, nonepithelioid MPM harbored fewer CNAs than epithelioid MPM. These results differ from those of recent reports from Bueno et al., 9 who found no differences in somatic mutation rates between histotypes. However, CNAs and point mutations arise from distinct mutational processes, and it is not surprising that patterns observed in one mutation class would not necessarily reflect the other. If MPM is a class C tumor driven more strongly by CNAs than point mutations (as suggested by the low mutation rate), our assessment of PGA would then be more likely to detect differences in genomic instability among subtypes than would comparing point mutation rates.
Using a TMA in lieu of full sections is subject to sampling error, and this could be considered a limitation of this study. To reduce this, we sampled three cores from separate areas of the tumor. TMAs allow efficient assessment of large cohorts and as such have been used to assess PD-L1 and immune infiltrates for a multitude of malignancies. 33, 34 Also, high concordance between TMA and whole sections in the evaluation of IHC in mesothelioma has been previously demonstrated, although our study focuses not just on tumor expression but also on immune cell infiltrates, which may not be as concordant across a sample. 35 Our characterization of the immunological infiltrates, PD-L1, and CNAs in MPM provides important data from a large patient cohort. Our data suggest that the immune axis is a valid target in MPM; however, single-agent immune checkpoint inhibitors are unlikely to be effective in most patients with MPM, given the low rates of strong PD-L1 expression and previous data confirming low mutational burden. As combination immune checkpoint inhibition threatens to shift treatment paradigms in melanoma and NSCLC, these data provide further rationale for implementation of such combinations in this rare but deadly disease.
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